The Case for Investment in R&D

The TB epidemic requires novel approaches, new tools and sufficient resources to mitigate what is now a more challenging and expensive disease to control than when the World Health Organization declared it a global emergency more than 20 years ago. New vaccines are urgently needed to protect against all forms of TB and would represent the single greatest preventative tool against the epidemic.

To advance the argument that more investments in TB vaccine R&D are crucial, Aeras, the TuBerculosis Vaccine Initiative (TBVI) and the European Commission, under the guidance of the European Investment Bank’s Research, Development and Innovation (RDI) Advisory Services, produced “TB Vaccine Research & Development: A Business Case for Investment.” The first ever model to look at innovative financing mechanisms for tuberculosis vaccines using a robust market analysis, this comprehensive report:

    • Demonstrates that a viable global market exists for new TB vaccines, thus calling for adequate financing on a risk-sharing basis among the public and private sectors
    • Presents ways the public and private sectors can blend finance in order to ensure adequate risk sharing between the sectors and to facilitate the development of new TB vaccines in the most cost-effective manner
    • Identifies product development strategies aimed at maximizing the public health impact of new TB vaccines
    • Estimates the portfolio development costs and time to market
    • Recommends the implementation of portfolio management as the most efficient and effective mechanism to advance the global vaccine pipeline
    • Shows that the investment needed for a preventive vaccine is a fraction of what it would cost to treat one of the world’s deadliest and most expensive infectious diseases, now estimated to cost upwards of $24 billion to support low- and middle-income countries through 2015 alone

In order to make new TB vaccines available for the world as soon as possible and in the most cost-effective way, sustainable financing and the implementation of a streamlined, rational portfolio management approach are required.